Helix BioPharma (TSX:HBP) GF Score: 33/100 (As of Jul. 10, 2026) — Near Median


TSX:HBP Helix BioPharma Corp TSX:HBP
33 GF Score
Price C$1.44
View Full Analysis

What is Helix BioPharma GF Score?

Helix BioPharma TSX:HBP +3.24% 33 GF Score is 33 as of Jul. 10, 2026, which is 3% below its 10-year median of 34.00. GuruFocus rates TSX:HBP with a GF Score™ of 33/100.

Helix BioPharma has the GF Score of 33, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 10/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Helix BioPharma might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Helix BioPharma  (TSX:HBP) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Helix BioPharma GF Score Related Terms

TSX:HBP vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Helix BioPharma's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helix BioPharma GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's GF Score distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's GF Score falls into.


TSX:HBP
33GF Score
Helix BioPharma Corp TSX:HBP
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 33 mean?
Helix BioPharma (TSX:HBP) has a GF Score of 33 as of Jul. 10, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Helix BioPharma and its competitors. This is near median its historical median of 34.00. Over the past decade, Helix BioPharma's GF Score has ranged from 20.00 to 45.00.
Is Helix BioPharma's GF Score too high?
Helix BioPharma's current GF Score of 33 is near median its 10-year median of 34.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 45.00. Overall, Helix BioPharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's GF Score compare to VRTX and REGN?
Helix BioPharma's GF Score of 33 can be compared against companies in the Biotechnology industry. Historically, Helix BioPharma's own GF Score has ranged from 20.00 to 45.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current GF Score is 33, which is near median its own 10-year median of 34.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (TSX:HBP) has a current GF Score of 33. The current GF Score is 33, which is near median its 10-year median of 34.00. Helix BioPharma's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Helix BioPharma (TSX:HBP), the current GF Score is 33 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBPCF:USAHBP0:Germany
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
33GF Score

Get the complete analysis for TSX:HBP

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.44
Price